Chimerix (Nasdaq:CMRX) - Stock Price, News & Analysis

CMRX Stock Overview

A biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases.

CMRX fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	6/6
Dividends	0/6

Rewards

Trading at 99.5% below our estimate of its fair value

Revenue is forecast to grow 62.97% per year

Risk Analysis

Makes less than USD$1m in revenue ($144K)

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($84M)

Chimerix, Inc. Competitors

Cidara Therapeutics

NasdaqCM:CDTX

US$81.6m

PMV Pharmaceuticals

NasdaqGS:PMVP

US$81.4m

Boundless Bio

NasdaqGS:BOLD

US$75.7m

Connect Biopharma Holdings

NasdaqGM:CNTB

US$70.8m

Price History & Performance

Summary of all time highs, changes and price drops for Chimerix
Historical stock prices
Current Share Price	US$0.87
52 Week High	US$1.30
52 Week Low	US$0.75
Beta	1.11
11 Month Change	5.45%
3 Month Change	-7.06%
1 Year Change	-21.20%
33 Year Change	-87.58%
5 Year Change	-58.92%
Change since IPO	-95.39%

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Jul 16

Recent updates

Chimerix expands oncology program with acquisition of Oncoceutics, shares up 10%

Jan 08

Who Has Been Buying Chimerix, Inc. (NASDAQ:CMRX) Shares?

Jan 01

Chimerix rises 9.1% premarket after FDA accepts NDA for smallpox countermeasure

Dec 07

Chimerix (NASDAQ:CMRX) Is In A Good Position To Deliver On Growth Plans

Dec 05

Chimerix, Inc. 2020 Q3 - Results - Earnings Call Presentation

Nov 08

Shareholder Returns

	CMRX	US Biotechs	US Market
7D	-11.8%	-2.1%	-1.9%
1Y	-21.2%	13.4%	20.9%

Return vs Industry: CMRX underperformed the US Biotechs industry which returned 14% over the past year.

Return vs Market: CMRX underperformed the US Market which returned 22.7% over the past year.

Price Volatility

Is CMRX's price volatile compared to industry and market?
CMRX volatility
CMRX Average Weekly Movement	9.0%
Biotechs Industry Average Movement	10.5%
Market Average Movement	6.3%
10% most volatile stocks in US Market	15.0%
10% least volatile stocks in US Market	3.1%

Stable Share Price: CMRX has not had significant price volatility in the past 3 months.

Volatility Over Time: CMRX's weekly volatility (9%) has been stable over the past year.

About the Company

Founded	Employees	CEO	Website
2000	72	Mike Andriole	www.chimerix.com

Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2.

Chimerix, Inc. Fundamentals Summary

How do Chimerix's earnings and revenue compare to its market cap?
CMRX fundamental statistics
Market cap	US$83.55m
Earnings (TTM)	-US$84.70m
Revenue (TTM)	US$144.00k

539.6x

P/S Ratio

-0.9x

P/E Ratio

Is CMRX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CMRX income statement (TTM)
Revenue	US$144.00k
Cost of Revenue	US$70.31m
Gross Profit	-US$70.17m
Other Expenses	US$14.53m
Earnings	-US$84.70m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.94
Gross Margin	-48,727.78%
Net Profit Margin	-58,820.14%
Debt/Equity Ratio	0%

How did CMRX perform over the long term?

See historical performance and comparison

CMRX Stock Overview

Rewards

Risk Analysis

Chimerix, Inc. Competitors

NasdaqCM:CDTX

US$81.6m

NasdaqGS:PMVP

US$81.4m

NasdaqGS:BOLD

US$75.7m

NasdaqGM:CNTB

US$70.8m

Price History & Performance

Recent News & Updates

Chimerix, Inc. to Report Q2, 2024 Results on Aug 13, 2024

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 36%

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023)

Recent updates

Chimerix, Inc. to Report Q2, 2024 Results on Aug 13, 2024

We're Keeping An Eye On Chimerix's (NASDAQ:CMRX) Cash Burn Rate

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Chimerix Receives Notice from Nasdaq Due to Non-Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates fall by 36%

First quarter 2024 earnings released: US$0.24 loss per share (vs US$0.24 loss in 1Q 2023)

Price target decreased by 8.7% to US$7.00

Chimerix, Inc., Annual General Meeting, Jun 20, 2024

Chimerix, Inc. to Report Q1, 2024 Results on May 01, 2024

Chimerix Appoints Marc D. Kozin to Board of Directors

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q4, 2023 Results on Feb 29, 2024

Chimerix Announces Board Changes

Chimerix, Inc. Promotes Michelle Laspaluto to the Position of Chief Financial Officer

Chimerix, Inc. Appoints Michelle Laspaluto to Chief Financial Officer

Chimerix, Inc. Appoints Thomas Riga as Chief Operating and Commercial Officer

Consensus revenue estimates fall by 22%

New minor risk - Profitability

Third quarter 2023 earnings released: US$0.27 loss per share (vs US$2.75 profit in 3Q 2022)

Chimerix, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Chimerix Announces Data Highlighting Clinical Efficacy and Molecular Mechanisms of Response to Onc201 Treatment of H3 K27m-Mutant Diffuse Midline Gliomas Published in Cancer Discovery

Consensus revenue estimates decrease by 48%, EPS upgraded

New minor risk - Market cap size

Price target decreased by 8.3% to US$7.33

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Chimerix, Inc. Announces Executive Changes, Effective on August 1, 2023

Chimerix, Inc.(NasdaqGM:CMRX) dropped from Russell 2000 Growth Index

CEO, President & Director recently bought US$98k worth of stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues and EPS in line with analyst expectations

Insufficient new directors

Chimerix, Inc. Announces Successful Launch of ONC201 Phase 3 Action Study

Price target decreased to US$8.00

Rubric Capital Management Sends Letter to Chimerix

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Emergent BioSolutions Inc. (NYSE:EBS) completed the acquisition of Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $370 million.

Price target decreased to US$8.00

Chief Business Officer exercised options to buy US$111k worth of stock.

Chimerix: Advancement For Rare Brain Cancer Drug Targeting Specific Mutation

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Chimerix, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Here's Why We're Watching Chimerix's (NASDAQ:CMRX) Cash Burn Situation

Chimerix: Down But Not Out

Price target decreased to US$8.20

Emergent BioSolutions Inc. (NYSE:EBS) entered into an agreement to acquire Exclusive Worldwide Rights to Brincidofovir, Including TEMBEXA® from Chimerix, Inc. (NasdaqGM:CMRX) for approximately $340 million.

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Chimerix, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

Consensus EPS estimates fall by 23%

Consensus estimates of losses per share improve by 44%

No longer forecast to breakeven

No longer forecast to breakeven

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Chimerix, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Chimerix, in Collaboration with the Rapidly Emerging Antiviral Drug Development Initiative Announces Late-Breaking Oral Presentation At International Conference on Antiviral Research

Chimerix, Inc. Announces Publication of Positive ONC201 Data from Phase 2 Study in Neuroendocrine Tumors in Clinical Cancer Research

Chimerix: Searching For Clarity

Forecast to breakeven in 2024